Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AER002 in Long COVID
NCT05877508Phase 2Active, not recruiting
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of AER002 in post-acute sequelae of SARS-CoV-2 infection (PASC). Started Aug 2023; status: active, not recruiting.
02
Drugs
AER002
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT05877508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05877508.